If you’ve seen headlines saying peptides like BPC-157, Thymosin Alpha-1, and CJC-1295 are “legal again,” you’re getting an incomplete picture.
Here’s what actually happened:
HHS announced its intent to reclassify 14 peptides from Category 2 (restricted from compounding) back to Category 1 (eligible for compounding). Multiple independent sources — including BioStrata Research and OpenLoop Health — have confirmed that as of March 16, 2026, no Federal Register notice has been published to formalize this change.
That means:
• The 14 peptides technically remain Category 2.
• Compounding pharmacies cannot legally prepare them under the current framework.
• Approximately 5 of the 14 may remain restricted even after formal rulemaking.
• No confirmed timeline for publication exists.
Why this matters for you:
Acting on announcements instead of regulations is exactly the kind of mistake the biohacking space is prone to. Intent is not policy. Headlines are not guidance.
Meanwhile, another signal arrived this period: Peptide Sciences — one of the largest U.S.-based research peptide vendors — voluntarily shut down operations on March 6, 2026. Independent testing platform Finnrick confirmed the closure and warned that any site still operating under the brand is fraudulent.
The regulatory environment has shifted from tolerance to active enforcement. Understanding where the lines actually are has never been more important.
— The Biohacker Network